Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136219

Published: 2020

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

Disease Factors and Not Comorbidity Drives Clinical Decisions in Elderly Patients with Follicular Lymphoma

Prathima Reddy, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Mazyar Shadman, MD, Edus H. Warren, III, MDPhD, Andrei Shustov, MD, Ryan D. Cassaday, MD, Oliver W. Press, MD PhD, Stephen D. Smith, MD

Blood (2017) 130 (Supplement 1): 2119.

https://doi.org/10.1182/blood.V130.Suppl_1.2119.2119

Published: 2017

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Andrei Shustov, MD, Maria Elena Cabrera, Monica Bellei, MSc, PhD, Young Hyeh Ko, MD, Martina Manni, PhD, Steven M. Horwitz, MD, Carmino Antonio De Souza, MD PhD, John A. Radford, MD, Sabela Bobillo Varela, Maria Virginia Prates, MD, Andrés J M Ferreri, MD, Carlos Chiattone, MD, Michele Spina, MD, Julie M. Vose, MDMBA, Annalisa Chiappella, MD, Daniele Laszlo, MD, Dario Marino, MDPhD, Caterina Stelitano, Massimo Federico, MD

Blood (2017) 130 (Supplement 1): 4071.

https://doi.org/10.1182/blood.V130.Suppl_1.4071.4071

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Blood (2017) 130 (Supplement 1): 4072.

https://doi.org/10.1182/blood.V130.Suppl_1.4072.4072

Published: 2017

Journal Articles

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Francine M Foss, MD, Steven M Horwitz, MD, Lauren Pinter-Brown, MD, Andre Goy, MD, Barbara Pro, MD, Bertrand Coiffier, MD, PhD, Leslie Popplewell, M.D., Kerry Joanne Savage, MD, BSc, MSc, Andrei Shustov, MD, Jasmine M. Zain, MD, Tony Koutsoukos, Steven M. Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2010) 116 (21): 1762.

https://doi.org/10.1182/blood.V116.21.1762.1762

Published: 2010

Journal Articles

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Andrei Shustov, MD, Barbara Pro, MD, Christian Gisselbrecht, MD, Leslie Popplewell, M.D., Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Jasmine M. Zain, MD, Faith Young, Richard R. Furman, MD, Steven M. Fruchtman, MD, Steven M Horwitz, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4882.

https://doi.org/10.1182/blood.V116.21.4882.4882

Published: 2010

Journal Articles

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, H. Miles Prince, MD, FRACP, FRCPA, Francine M Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei Shustov, MD, Jean Nichols, Susan Carroll, John Balser, PhD, Steven M Horwitz, MD

Blood (2010) 116 (21): 114.

https://doi.org/10.1182/blood.V116.21.114.114

Published: 2010

Journal Articles

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Pamela S. Becker, MD, PhD, Hagop Kantarjian, MD, Frederick R. Appelbaum, MD, Stephen H. Petersdorf, MD, Barry Storer, PhD, Sherry A. Pierce, RN, BS, Jianqin Shan, PhD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Andrei Shustov, MD, Derek L. Stirewalt, MD, Stefan Faderl, MD, Elizabeth Harrington, RN, Elihu H. Estey, MD

Blood (2010) 116 (21): 1065.

https://doi.org/10.1182/blood.V116.21.1065.1065

Published: 2010

Journal Articles

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Steven M Horwitz, Youn H. Kim, MD, Francine M Foss, MD, Jasmine M. Zain, MD, Patricia Myskowski, MD, Mary Jo Lechowicz, MD, David C. Fisher, MD, Andrei Shustov, MD, Nancy L. Bartlett, MD, Maria L Delioukina, MD, Tony Koutsoukos, PhD, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD, Madeleine Duvic, MD

Blood (2010) 116 (21): 2800.

https://doi.org/10.1182/blood.V116.21.2800.2800

Published: 2010

Journal Articles

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Lihua E Budde, MD., PhD, Andrei Shustov, MD, John M. Pagel, MD, PhD, Ted Gooley, PhD, George Oliviera, MD, Tara Chen, PharmD, Michelle Zhang, MD, Thomas A. Warr, MD, Thomas Boyd, MD, Oliver W. Press, MD, PhD, Ajay K Gopal, MD

Blood (2010) 116 (21): 2790.

https://doi.org/10.1182/blood.V116.21.2790.2790

Published: 2010

Journal Articles

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B 12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, MD, PhD, Barbara Pro, M.D., Lauren Pinter-Brown, MD, Leslie Popplewell, MD, Nancy Barlett, MD, Andrei Shustov, MD, Mary Jo Lechowicz, MD, Kerry J Savage, MD, MSc, Bertrand Coiffier, MD, Eric Jacobsen, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Jasmine Zain, MD, Shannon Wilroy, Molly Patterson, Adam Boyd, Michael E. Saunders, MD, Pablo Cagnoni, MD, Steven M. Horwitz, MD

Blood (2008) 112 (11): 261.

https://doi.org/10.1182/blood.V112.11.261.261

Published: 2008

Journal Articles

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Derek Stirewalt, MD, Andrei Shustov, MD, Barry E. Storer, PhD, Frederick R. Appelbaum, MD

Blood (2008) 112 (11): 2964.

https://doi.org/10.1182/blood.V112.11.2964.2964

Published: 2008

Journal Articles

A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma

Aj ay K Gopal, MD, Oliver W. Press, MD, PhD, Andrei Shustov, MD, Stephen Petersdorf, MD, Ted Gooley, PhD, Jasmine T. Daniels, MD, Mitchell Garrison, MD, George Gjerset, MD, Matthew Lonergan, MD, Anne Murphy, MD, Julie Smith, MD, John M. Pagel, MD, PhD

Blood (2008) 112 (11): 2585.

https://doi.org/10.1182/blood.V112.11.2585.2585

Published: 2008

NARROW

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Disease Factors and Not Comorbidity Drives Clinical Decisions in Elderly Patients with Follicular Lymphoma

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B 12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only